<DOC>
	<DOCNO>NCT03019029</DOCNO>
	<brief_summary>The primary aim study examine diagnostic utility 18-F Florbetapir PET/MR ( Positron Emission Tomography/Magnetic Resonance ) image patient pathologically-confirmed systemic amyloidosis involve peripheral nerve compare result non-amyloid diseased control .</brief_summary>
	<brief_title>Diagnostic Utility F-18 Florbetapir PET/MR Peripheral Nerve Amyloidosis</brief_title>
	<detailed_description>Patients pathologically proven amyloidosis involve peripheral nervous system undergo 18-F Florbetapir PET/MR GE ( General Electric Healthcare ) SIGNA PET/MR scanner . A control arm comprise patient pathologically-confirmed non-amyloid cause peripheral neuropathy also undergo 18-F Florbetapir PET/MR scan . image review peripheral nerve uptake .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Adults : 18100 Pathologicallyconfirmed peripheral nerve amyloidosis pathologicallyconfirmed nonamyloid cause peripheral neuropathy Metallic device MR safe ( cardiac pacer , stent , aneurysm coil , etc . ) Claustrophobia BMI 38</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peripheral Nerve Amyloidosis</keyword>
</DOC>